To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

POLD1 L606M - Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene POLD1
Variant L606M
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions POLD1 L606M lies within the polymerase domain of the Pold1 protein (PMID: 27093186). L606M results in increased polymerase activity and exonuclease activity but increased base substitution error rate and mutational rate compared to wild-type Pold1 (PMID: 19540301), and therefore is predicted to lead to a loss of Pold1 protein function.
Associated Drug Resistance
Category Variants Paths

POLD1 mutant POLD1 inact mut POLD1 L606M

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_002691.4
gDNA chr19:g.50408825C>A
cDNA c.1816C>A
Protein p.L606M
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_047438948.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_047438946.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_047438950.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
NM_001256849.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_047438947.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_017026882.3 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_011527038.2 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
NM_001308632.1 chr19:g.50408747_50408749delCTAinsATG c.1816_1818delCTAinsATG p.L606M RefSeq GRCh38/hg38
XM_047438949.1 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
XM_005259008.5 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38
NM_002691.4 chr19:g.50408825C>A c.1816C>A p.L606M RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
POLD1 L606M colorectal cancer predicted - sensitive Pembrolizumab Case Reports/Case Series Actionable In a retrospective study, treatment with immune checkpoint inhibitors resulted in an overall response rate of 89% (22/29) and a disease control rate of 92% in metastatic colorectal cancer patients harboring pathogenic POLE/POLD1 variants, including a partial response in a patient harboring POLD1 L606M treated with Keytruda (pembrolizumab) (PMID: 38777726). 38777726